Inhibikase Therapeutics Income Statement (2020-2025) | IKT

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter)
1.41M1.36M0.33M0.00M0.05M0.01M0.01M0.06M0.06M0.12M0.08M1.00
Operating items
Research & Development (Quarter)
2.43M2.38M3.15M3.39M3.02M2.98M2.98M3.05M2.85M4.54M3.23M13.59M2.75M3.08M4.19M7.19M10.51M5.27M7.65M6.36M
Selling, General & Administrative (Quarter)
1.60M1.61M1.64M1.65M1.67M1.66M1.54M1.34M1.93M1.78M1.62M1.40M2.03M1.97M1.64M5.74M5.25M5.92M5.61M6.77M
Other Operating Expenses (Quarter)
-10.59M-1.16M-0.36M-0.49M0.64M
Operating Expenses (Quarter)
4.03M3.99M4.80M5.04M4.69M4.65M4.52M4.40M4.78M6.32M4.85M4.40M4.78M5.05M5.83M12.93M14.60M10.83M12.77M13.78M
Operating Income (Quarter)
-2.63M-2.63M-4.47M-5.04M-4.64M-4.64M-4.51M-4.33M-4.71M-6.20M-4.77M-4.40M-4.78M-5.05M-5.83M-12.93M-14.60M-10.83M-12.77M-13.78M
EBIT (Quarter)
-2.63M-2.63M-4.47M-5.04M-4.64M-4.64M-4.51M-4.33M-4.71M-6.20M-4.77M-4.40M-4.78M-5.05M-5.83M-12.93M-14.60M-10.83M-12.77M-13.78M
Non-operating items
Non Operating Investment Income (Quarter)
0.03M-0.17M0.00M-0.00M776.000.00M-0.04M0.04M-0.00M-0.00M0.03M
Interest & Investment Income (Quarter)
0.02M
Net income details
EBT (Quarter)
-2.64M-2.64M-4.47M-5.04M-4.64M-4.64M-4.49M-4.33M-4.71M-6.20M-4.77M-4.40M-4.78M-5.05M-5.83M-12.93M-14.60M-10.83M-12.77M-13.78M
Profit After Tax (Quarter)
-2.64M-2.64M-4.47M-5.04M-4.64M-4.64M-4.49M-4.28M-4.48M-5.78M-4.60M-4.18M-4.65M-4.96M-5.78M-12.13M-13.68M-9.92M-11.93M-12.73M
Income from Continuing Operations (Quarter)
-2.64M-2.64M-4.47M-5.04M-4.64M-4.64M-4.49M-4.33M-4.71M-6.20M-4.77M-4.40M-4.78M-5.05M-5.83M-12.93M-14.60M-10.83M-12.77M-13.78M
Consolidated Net Income (Quarter)
-2.64M-2.64M-4.47M-5.04M-4.64M-4.64M-4.49M-4.33M-4.71M-6.20M-4.77M-4.40M-4.78M-5.05M-5.83M-12.93M-14.60M-10.83M-12.77M-13.78M
Income towards Parent Company (Quarter)
-2.64M-2.64M-4.47M-5.04M-4.64M-4.64M-4.49M-4.33M-4.71M-6.20M-4.77M-4.40M-4.78M-5.05M-5.83M-12.93M-14.60M-10.83M-12.77M-13.78M
Net Income towards Common Stockholders (Quarter)
-2.64M-2.64M-4.47M-5.04M-4.64M-4.64M-4.49M-4.33M-4.71M-6.20M-4.77M-4.40M-4.78M-5.05M-5.83M-12.93M-14.60M-10.83M-12.77M-13.78M
Additional items
EPS (Basic) (Quarter)
-0.26-0.22-0.18-0.20-0.18-1.10-1.06-1.02-0.98-1.11-0.75-0.68-0.73-0.66-0.650.87-0.15-0.11-0.13-0.09
EPS (Weighted Average and Diluted) (Quarter)
-0.22-0.18-0.20-0.18-1.10-1.06-1.02-0.98-0.94-0.75-0.68-0.73-0.66-0.650.87-0.15-0.11-0.13-0.09
Shares Outstanding (Weighted Average) (Quarter)
10.05M11.15M25.14M18.21M25.21M4.22M4.22M4.22M5.58M6.16M5.98M6.03M6.34M7.54M8.88M23.71M89.54M89.77M90.05M
Shares Outstanding (Diluted Average) (Quarter)
11.15M15.87M18.21M25.21M4.22M4.22M4.22M5.58M6.16M5.98M6.03M6.34M7.54M8.88M23.71M89.54M89.77M89.87M
EBITDA (Quarter)
-2.63M-2.63M-4.47M-5.04M-4.64M-4.64M-4.47M-4.33M-4.71M-5.95M-4.59M-4.40M-4.78M-5.05M-5.83M-12.93M-14.60M-10.83M-12.77M-13.78M
Interest Expenses (Quarter)
0.01M0.01M157.00158.005.00